- GeoVax to Participate in BIO International Convention 2025
- GeoVax Responds to WHO’s Fourth Declaration of Mpox as a Global Public Health Emergency
- GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients
- GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia
- GeoVax to Showcase Innovative COVID 19 Vaccine Data at the Keystone Symposia on Vaccinology
- GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing
- GeoVax Commends FDA’s Shift to Risk-Based COVID-19 Vaccination Guidance
- GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation
- GeoVax Reaffirms Urgent Need for Multi-Antigen COVID-19 Vaccines as CDC Shifts Recommendations
- GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025
- GeoVax Expands Gedeptin(R) Patent Portfolio
- GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production
- GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update
- GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting
- GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater
- GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress
- GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025
- GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations
- GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum
- GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates
- GeoVax to Present Clinical Data at Upcoming April Industry Events
- GeoVax to Present at the Emerging Growth Conference on April 16, 2025
- GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent
- GeoVax Reports 2024 Year-End Financial Results and Provides Business Update
- GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- GeoVax to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
- GeoVax Establishing Strategic Presence in Europe with Initial Footprint in the UK
- GeoVax to Present at the 37th Annual Roth Conference
- Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event “MPOX 2025: Navigating the Global Public Health Emergency” Featuring GeoVax CEO On March 6, 2025
- GeoVax Highlights the Critical Role of MVA-Based Vaccines in U.S. Biodefense Strategy
- GeoVax Response to WHO’s Third Declaration of Mpox as a Public Health Emergency of International Concern
- GeoVax Highlights the Role of MVA-Based Vaccines in Advancing Public Health Preparedness
- Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification
- GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health
- GeoVax to Present at the Emerging Growth Conference on February 19, 2025
- GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award
- GeoVax Anticipates Significant 2025 Progress with Catalyst-Rich Milestones Across Key Programs
- GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference
- GeoVax Announces Strategic Integration of AI in Support of President Trump’s Stargate Initiative
- Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability
- GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide
- GeoVax Announces Major Gedeptin® Milestone with Plans of Phase 2 Trial
- GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024
- GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025
- GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025
- GeoVax Receives Notice of Allowance For Cancer Vaccine Patent
- GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference
- GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
- GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
- GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024
